Celiprolol

Summary

Celiprolol is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.

Celiprolol
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Pharmacokinetic data
Bioavailability30-70%
Elimination half-life5 hours
Identifiers
  • (RS)-N'-{3-Acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
CAS Number
  • 56980-93-9
PubChem CID
  • 2663
DrugBank
  • DB04846 checkY
ChemSpider
  • 2563
UNII
  • DRB57K47QC
KEGG
  • D07660
ChEMBL
  • ChEMBL27810
CompTox Dashboard (EPA)
  • DTXSID3020259 Edit this at Wikidata
ECHA InfoCard100.054.980 Edit this at Wikidata
Chemical and physical data
FormulaC20H33N3O4
Molar mass379.501 g·mol−1
3D model (JSmol)
  • Interactive image
ChiralityRacemic mixture
  • O=C(N(CC)CC)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(=O)C

It was patented in 1973 and approved for medical use in 1982.[1]

Medical use edit

Celiprolol is believed to provide clinical benefit for people with vascular Ehlers–Danlos syndrome by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture.[2] In 2019, a new drug application (NDA) for celiprolol was denied by the U.S. Food and Drug Administration (FDA), instead calling for an “adequate and well-controlled” trial to determine whether celiprolol reduced the risk of clinical events in patients with vEDS. [3]

Brand names edit

Brand names include Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm

References edit

  1. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 461. ISBN 9783527607495.
  2. ^ Beridze N, Frishman WH (2012). "Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications". Cardiology in Review. 20 (1): 4–7. doi:10.1097/CRD.0b013e3182342316. PMID 22143279. S2CID 9339508.
  3. ^ Campbell P (25 June 2019). "FDA Denies NDA for Celiprolol". MD Magazine.

External links edit

  • Selectol Summary of Product Characteristics (from the IPHA Medicines Compendium)
  • Celiprolol data sheet for New Zealand